Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility)
Completed
Esperion Therapeutics
Phase 3
2016-11-29
The purpose of this study is to determine if bempedoic acid (ETC-1002) added-on to ezetimibe
therapy is effective and safe versus placebo in patients with elevated LDL cholesterol.
Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility)
Completed
Esperion Therapeutics, Inc.
Phase 3
2016-11-29
The purpose of this study is to determine if bempedoic acid (ETC-1002) added-on to ezetimibe
therapy is effective and safe versus placebo in patients with elevated LDL cholesterol.
Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C
Completed
Esperion Therapeutics
Phase 2
2017-01-19
The purpose of this study is to determine if triplet therapy with bempedoic acid (ETC-1002)
180mg, ezetimibe 10mg, and atorvastatin 20mg is effective and safe versus placebo in patients
with elevated LDL cholesterol.
Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C
Completed
Esperion Therapeutics, Inc.
Phase 2
2017-01-19
The purpose of this study is to determine if triplet therapy with bempedoic acid (ETC-1002)
180mg, ezetimibe 10mg, and atorvastatin 20mg is effective and safe versus placebo in patients
with elevated LDL cholesterol.
A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy
Completed
Esperion Therapeutics
Phase 3
2017-10-23
The purpose of this study is to determine if Bempedoic Acid (BA) + Ezetimibe (EZE) in a
fixed-dose combination (FDC) is effective and safe versus its individual components and
placebo in patients with elevated LDL cholesterol treated with maximally tolerated statin
therapy.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
